Inhaled steroids and mortality in COPD: bias from unaccounted immortal time
- 1 March 2004
- journal article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 23 (3) , 391-395
- https://doi.org/10.1183/09031936.04.00062504
Abstract
A recent observational study, which suggested that inhaled corticosteroids (ICS) with or without long-acting bronchodilators are effective at reducing all-cause mortality in chronic obstructive pulmonary disease (COPD) patients, may be subject to immortal time bias.This bias was assessed using a population-based cohort of 3,524 newly treated COPD patients from Saskatchewan, Canada, observed from 1990–1999. Regular users of bronchodilators or ICS were followed for 3 yrs, during which time 860 deaths occurred. Cox's proportional hazards model was used to compare the hierarchical intention-to-treat approach employed in the recent study, a technique subject to bias from two sources of immortal time, with the conventional intention-to-treat approach and the according-to-treatment approach.The adjusted rate ratio of death using the hierarchical intention-to-treat approach was 0.66 (95% confidence interval (CI) 0.57–0.76) for ICS use relative to bronchodilator use, compared with 0.75 (95% CI 0.62–0.90) with the conventional intention-to-treat approach. Conversely, the rate ratio was 0.94 (95% CI 0.81–1.09) with the according-to-treatment approach, which accounts for both sources of immortal time.In this study, regular inhaled corticosteroid use in chronic obstructive pulmonary disease was not found to reduce all-cause mortality. Suggestion of this benefit from a previous observational study is the result of bias from unaccounted immortal time in its cohort design and analysis.Keywords
This publication has 21 references indexed in Scilit:
- Effectiveness of Inhaled Corticosteroids in Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter?European Respiratory Journal, 2003
- Inhaled short acting beta agonist use in COPD and the risk of acute myocardial infarctionThorax, 2003
- Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practiceEuropean Respiratory Journal, 2002
- Effect of Inhaled Triamcinolone on the Decline in Pulmonary Function in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2000
- Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trialBMJ, 2000
- Long-Term Treatment with Inhaled Budesonide in Persons with Mild Chronic Obstructive Pulmonary Disease Who Continue SmokingNew England Journal of Medicine, 1999
- Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trialThe Lancet, 1999
- Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary diseaseThe Lancet, 1998
- Do patients with COPD benefit from treatment with inhaled corticosteroids?European Respiratory Journal, 1996